Find a Trial

Trial Summary


Protocol No.CTO-TTX-080-001
StatusOPEN TO ACCRUAL
Principal InvestigatorDurm, Greg
ScopeNational
PhasePhase I
Age GroupAdult
TitleA first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors
DescriptionTTX-080-01 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Subject with histological diagnosis of advanced/metastatic cancer
  • Evidence of measurable disease
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632
    Email: iutrials@iu.edu